Guoqing Cao

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Antibody Therapeutics. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guoqing Cao. Retrieved from https://idiyas.com/inventor/guoqing-cao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 88.2

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 4 (Patent Applications = 13)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 30(Granted Patents)

Location History:

Lianyungang, CN (2019 - 2022)
Shanghai, CN (2017 - 2023)
Jiangsu, CN (2021 - 2024)

Company Filing History:

14 out of 159

Jiangsu Hengrui Medicine Company Ltd.

patents

10 out of 100

Shanghai Hengrui Pharmaceutical Co., Ltd.

patents

6 out of 8

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

patents

4. 2 out of 2

Minghui Pharmaceutical (Hangzhou) Limited

patents

5. 2 out of 2

Minghui Pharmaceutical (Shanghai) Limited

patents

6. 1 out of 1

Cytolynx Therapeutics Hong Kong Limited

patent

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Antibody-Drug Conjugate

Monoclonal Antibody

PD-1 Inhibitor

VEGFR Inhibitor

Bruton's Tyrosine Kinase

KOR Agonist

EZH2 Inhibitor

PARP Inhibitor

Tumor Treatment

Pain Management

Cancer Therapy

Heterodimeric Protein

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698292 - Toxin molecule suitable for antibody-drug conjugate (2026-08-04),

2. 12479922 - HUMANIZED MONOCLONAL ANTIBODY TARGETING BCMA AND HAVING HUMAN MONKEY CROSS-REACTIVITY (2025-11-25),

3. 12435144 - Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers (2025-10-07),

4. 12384786 - Cyclic molecules as Bruton's tyrosine kinase inhibitor (2025-08-12),

5. 11866500 - Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers (2024-01-09),

6. 11780923 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2023-10-10),

7. 11525005 - Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof (2022-12-13),

8. 11471503 - Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain (2022-10-18),

9. 11365255 - PD-1 antibody, antigen-binding fragment thereof, and medical application thereof (2022-06-21),

10. 11208484 - Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers (2021-12-28),

11. 11065239 - Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor (2021-07-20),

12. 11000518 - Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer (2021-05-11),

13. 10815304 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2020-10-27),

14. 10344090 - PD-1 antibody, antigen-binding fragment thereof, and medical application thereof (2019-07-09),

15. 10206980 - IL-15 heterodimeric protein and uses thereof (2019-02-19),

Title: The Journey of Inventor Guoqing Cao in the Pharmaceutical Field

Introduction

Guoqing Cao is a notable figure in the pharmaceutical industry, based in China. Despite having no registered patents to his name, he has accumulated valuable experience through his work in various capacities within prominent organizations.

Latest Patents

Currently, Guoqing Cao holds no patents. This indicates a focus on collaboration and application of existing technologies, rather than individual patent filings.

Career Highlights

Throughout his career, Guoqing has primarily worked at Minghui Pharmaceutical Limited. His contributions to this organization reflect his dedication to advancing pharmaceutical solutions. His role in such a significant company highlights his expertise in the field and ability to contribute to vital research and development initiatives.

Collaborations

In his professional journey, Guoqing Cao has collaborated with esteemed colleagues, including Zhaoyin Wang and Bing Yao. These partnerships demonstrate a collaborative spirit that is essential in the pursuit of innovations in the pharmaceutical sector.

Conclusion

Though Guoqing Cao may not have individual patents to showcase, his experience and collaborations within the pharmaceutical industry speak volumes about his contributions. His career reflects the essence of teamwork and perseverance in the realm of innovation and invention.

Profile summary based on public USPTO records.